

# 論文受理後の著者の手続きについて (転換契約に基づく契約機関に所属する 責任著者向け)

最終更新:2024年9月6日



# **Key information**

#### 1. 転換契約に基づく対象論文の適用はどのように決定されますか?

- 契約開始日以降に受理された論文であること。
- 責任著者が契約機関に所属していること。
- 論文が契約対象のジャーナルであること。
- 2. 契約の目的の上での責任著者はどのように定義されますか?
  - 責任著者とは、Elsevierのジャーナルへの投稿・出版に際し、最後までElsevierとの連絡窓口を 請け負う著者のこと。
  - 著者グループを代表して、出版に関する選択を行います。
  - 全ての論文において、責任著者が一人いる。
- 3. Elsevier Open Access Platform (EOAP)運用における図書館/管理者の役割
  - 論文が受理されると、通常48時間以内に論文の最初のバージョンがScienceDirectで出版されます\*。この 間にその論文がEOAPに追加されます。
     \*校正等、論文の個別の事情により、EOAPの登録までにお時間をいただく場合もあります。
  - 図書館/管理者が論文出版の承認、否認をするわけではありません。契約や機関ルールに基づき本論文が OA出版枠やAPC割引を適用できるかを判断します。
  - 図書館/管理者は契約管理者として、著者が契約の適用に該当するかどうかを決定する権限を有しています。

# Key information

- 4. 対象となる論文のタイプ
  - Case reports
  - Data in Briefs
  - Full-length articles
  - Micro-articles
  - Original software publication
  - Practice guidelines
  - Protocols
  - Review articles
  - Replication studies
  - Short communications
  - Short surveys
  - Video articles

# 論文受理後の手続きについて



### Author Journeyの開始

- 論文が受理された後、責任著者は出版のオ プションを選び、Author Journeyを完了さ せるための専用リンクをEメールで受け取 ります。
- Eメールの専用リンクを開いた 後、"Complete the rights and access form"をクリックします。

#### (1)

#### Finalize Publishing your Article

Corresponding author E-mail address	· · · · · · · · · · · · · · · · · · ·	-
Journal	Fuel	
Our reference		
РП		
Welcome Dr. Stanly,		
To help us finalize the publication Note: you will receive a confirmation	i of your article please complete the publishing form(s) below. tion e-mail after completing each form.	
-		
Information you may need t	o provide to complete the forms	~
Rights and Access		
Rights and Access		



## 責任著者の所属機関の入力

 責任著者は自身の所属機関の詳細を 選択します。その情報を基に契約機 関とのマッチングが行われます。

② 著者が投稿時に既にこの情報を提供している場合には、予め所属機関が 選択されていますのでご留意ください。

【注意】 表示されるプルダウンから正しい機関を 選択してください。

1	- 2	-(3)	-(4)	(5)	—( 6 )——	(7)		( • )	(10)	
Corresponding Author	Co-Author	Research Funders	Society Membership	Publishing Options	Licenses	Rights	Publishing Agreement	Review Order	Confirmation	
		Correspor E-mail ad Journal Our refere PII	nding author dress ence	Fuel					<u>^</u>	
		Corres Please ent article pul Hint: start select the more tips	ponding Auth ter the corresponding olishing charge for G t your search using y most appropriate op on searching for an	oor's Organizat g author's organizati iold open access whe our main organizati tion. If you're unabl organization please	tion ① on. We use this inf en applicable. on name (e.g. Univ e to find your spec visit our Support C	formation so we rersity of Manche ific department, ienter.	can offer tailored pu ester) as this will retu then selecting your	blishing options an urn the most result main organization i	d a personalized 5 from which to is sufficient. For	
	( <u>1</u> (2	Organizat waseda u Waseda U Shinjuku- Waseda U Shinjuku- Waseda U Shinjuku- Waseda U	ion name* iniversity Ku, JP Iniversity - Waseda G Ku, JP Iniversity Center for Ku, JP	Campus Advanced Biomedie Science and Engine	cal Sciences ering	Ī		Save	and Continue >	2
	All content on For all Open A	Shinjuku- t <b>Waseda U</b> c Shinjuku-	Ku, JP Iniversity Faculty of Ku, JP	Political Science and	d Economics	All rights (in litions 7 P	cluding all rights for rivacy Policy ㅋ Co	r TDM, AI training, okie Notice 🤊 Co	and similar technologi ntact us ㅋ	es) are reserved.
	Cookies are se	Waseda U Shinjuku, Waseda U	Iniversity - Toyama ( JP Iniversity - Tokoroza	ampus wa Campus					6	RELX Group™



### 共著者情報の入力

 責任著者は共著者の名前、 所属機関を入力します。

Rights and	d Access								
1 Corresponding Author	2 Co-Author	Research Funders	Publish Optio	ing Rights	Publishing Agreement	7 Review Order	Confirmation		
									~
				Were there any co-autho	rs for this article?	Yes     No			
				Add Co-author I Please provide details fo publishing charge for G Hint: start the organizat which to select the most For more tips on searchi	Details ① r all co-authors. W old open access wh ion search using th appropriate option ng for an organiza	e use this informatic en applicable. He main organization h. If you're unable to tion please visit our	e this information so we can offer tailored publishing options and a personalized article pplicable. ain organization name (e.g. University of Manchester) as this will return the most results from you're unable for the specific department, then selecting the main organization is sufficient. please visit our Support Center.		
			$\widehat{1}$	First name or initial* John			Last name* Head		Û
				Organization name* KU Leuven Or use recently selected	organization				
				+Add another co-autho	r				
				Previous				S	Save and Continue 义



### 資金提供者の情報入力

- ① 資金提供者の情報を追加できます。 資金提供者は所属機関、または別の機関でも構いません。
- ② 資金提供者の情報を追加する場合、 画面上部で[Yes]を選択し、下に詳 細情報を入力します。この例では、 [Milliman Inc]が資金提供者です。

Rights an	d Access		
1 Corresponding Author	2 Co-Author	3 Research Funders	4 6 7 8 Publishing Rights Publishing Review Order Confirmation Options Agreement
			Did the research in this article receive funding?
			Funder Details ① Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.
			For tips on searching for an organization please visit our Support Center Organization name* Milliman Inc Grant/Contract numbers* GT123 GT123
			+ Add grant/contract number
			+Add another organization
			Previous Save and Continue >



#### 出版モデルの選択

- ハイブリッドジャーナルの場合、出版オプションを選択 します。責任著者の所属機関情報に基づいて、Gold Open Accessで出版する場合、APCが全額カバーされる ことが表示されます。または購読モデルでの出版を選択 することができます。
- ② 管理者がEOAP上で申請を否認した場合、正規のAPC料金 の請求書が送付されることが記載されています。

※ご所属機関のお取決めにより、著者の方に一定のご負担 が生じる場合があります。詳細は、ご所属機関管理者にご確 認ください。

ここでは、Gold Open Accessを選択して次に続きます。





APC割引が適用される場合

- ① APC割引が適用される場合、割引金額が表示されます。
- ② 割引バウチャーをお持ちの場合、こちらから入力できます。(※割引率の大きい方のみが適用されます。)





### CCライセンスオプションの選択

- CCライセンスオプション選択が表示されます。
- CC BY 4.0、 CC BY-NC-ND 4.0、 CC BY-NC 4.0のいずれかのオプションを選択し ます。

エルゼビアのCCライセンスに関する情報は 以下をご参照ください。

https://www.elsevier.com/about/policies-andstandards/open-access-licenses/user

Righ	ts and Access	
1 Correspo	2 3 6 2 0 onding Co-Author Research Publishing Licenses Rights Publishing Review Order Confirmation	
Selea	t your user license	
Please Hub fo	select your license. If you need to comply with a mandated license and the mandated license is not listed below, please r additional help.	visit our Support
0	CC BY 4.0	
	A license to permit readers to share and adapt your article for any purpose, even commercially.	
	Read more about CC BY 4.0	~
0	CC BY-NC-ND 4.0	
	A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.	
	Read more about CC BY-NC-ND 4.0	~
0	CC BY-NC 4.0	
	A license for readers to share and adapt your article for non-commercial purposes. Permission from Elsevier is require commercial use of the article.	d for
	Read more about CC BY-NC 4.0	~



権利とステータスの確認



1 Corresponding Nuthor	2 Co-Author	3 Research Funders	4 Publishing Options	5 Licenses	6 Rights	Publishing Review Order Confirmation Agreement	
							×
					(1)	Elsevier B.V.	
					<u> </u>	Select Your Status	
						I am the sole author of the manuscript	
						I am one author signing on behalf of all co-authors of the manuscript	-
						We are a low of the other and the and the Article is public domain and therefore the 'License of publishing rights'	
						Clause does not apply I am a US Government employee but some of my co-authors are not	
						I am not a US Government employee but some of my co-authors are	
						O The work was performed by contractors of the US Government under contract number:	
						Contract Number*	
						All or some of the authors are UK. Canadian or Australian Government employees and Crown Copyright is asserted	
						Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted	
						None of the above	
						I am signing as an authorized representative and on behalf of my employer	
						Signed on Behalf of Corresponding Author	
						Please complete this section if you are not the corresponding author as listed above. A conv of the agreement will be sent to you and the	
						corresponding author.	
						I am signing on behalf of the corresponding author	
						Name, job title and company (if employer representative)*	
						E-mail address*	
						Previous Save and Continue	>



### 出版契約の情報

 ジャーナルのライセンス出版契約に関する情報 が表示されます。

#### **Rights and Access** Corresponding Co-Author Research Publishing Rights Publishing Review Order Confirmation Licenses Author Funders Options Agreement Elsevier B.V. Your Status · I am one author signing on behalf of all co-authors of the manuscript License of Publishing Rights I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties. Supplemental Materials "Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material. With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis. Research Data "Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.



### 出版契約の同意

#### ジャーナルのライセンス出版契約 に同意(最下部にチェック)して、 進んでください。

For further information see the publishing ethics page at https://www.elsevier.com/about/our-business/policies/publishing-ethics 71 and the journal home page. For further information on sanctions, see https://www.elsevier.com/about/our-business/policies/trade-sanctions 71

#### Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously
  published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- · Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity
  and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and compiled with the publisher's policies relating to the use of such images or personal information. See https://www.elswier.com/sbou/jour-business/policies/policies/policies/consent ... for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms
  of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

#### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright 7.

I have read and agree to the terms of the License Agreement.

T-copyright license-v5/2017

17 December 2021

Previous





# 請求書の情報入力(APC割引の場合のみ)

Rights and Ac

Corresponding Author

 請求書の送付先を記入します。 個人宛か機関宛を選択することが できます。

cess									
2 Author	3 Research Funders	4 Publishing Options	5 Licenses	6 Rights	7 Publishing Agreement	8 Payment Details	Review Order	Confirmation	
			-						~
			The invo your elig	ice address you ibility for the di	provide will be vis scount	ible to the insti	tution approving	Total	payment due Price (excluding taxe JPY 331,46
		(1	Invoice add	ress an Organization	۲	Invoice an Indiv	idual	Tax ① Tax	Institutional Agreement Discou - 66,29 amounts are indicative and will be
			<ul> <li>Please n an indivi</li> <li>If the inc contact i</li> </ul>	ote this option dual, not an org lividual is part o n the 'Invoice ar	should only be sel ganization. of an organization, n Organization' op	ected if you war . you can still sp tion, above.	nt Elsevier to Movie ecify them as a		To pr Total price (including taxe
			Title* Mr First name					If your i you will 2,950.00 invoice,	JPY 265,16 nstitution cannot confirm your affiliation receive a full price invoice for USD 0 (ex: VAT). Within 2 weeks of receiving an you may contact Researcher Support to for a 5 theorem of which Chevrienics
			Surname*					publish model. Waseda	rree or charge under the Subscription University and Elsevier Agreement
			Country or Rep	gion*			~		



# 請求書の情報入力(APC割引の場合のみ)

- ① 請求書送付先の情報を入力します

	India V	
	1100	Total payment due
1	Address Line 1*	Price (excluding taxes)
IJ		JPY 331,460
	Address Line 2	Institutional Associate Discuss
	To a real sector of the sector	命 - 66.292
	City*	
	The second se	Tax O
	Clain	<ul> <li>Tax amounts are indicative and will be confirmed on the invoice</li> </ul>
	Zip/Post Code*	To pay
	1000 C	
	E-mail*	Total price (including taxes)
		Z JPY 265,168
		If your institution cannot confirm your affiliation, you will receive a full price invoice for USD
	Phone number (including country code)*	2,950.00 (ex. VAT). Within 2 weeks of receiving an
		invoice, you may contact Researcher Support to publish free of charge under the Subscription
)	Purchase order number*	model.
		Waseda University and Elsevier Agreement
	VAT/CET/CET Desistentias Number 0	
	Does the individual have a VAT / GST / CST registration number?	
	bes de namada nare a sur y est y est registration namaer.	
	No the individual does not have a VAT / GST / CST registration number	
	Tes the individual does have a VAL/GSL/CSL registration number	
	Payment	
	How do you want to pay for the Article Publishing Charge? * ①	
	Credit / Debit card	
	Send an invoice	
	An invoice will be emailed to the address you have entered. Payment can be made	
	via bank transfer, credit card, or via telephone.	
	Previous	Save and Continue >
		Save and Continue 9



- 入力内容の確認
- ①入力した内容が表示されます。
- 確認して問題なければ[Finish]をクリックします。
- <u>[Finish]クリック後</u>
- ▶ 責任著者並びに共著者は確認のメールを受け 取ります。
- 論文は24時間以内にScienceDirectで公開され ます\*。(\*校正等、論文の個別の事情により、 EOAPの登録までにお時間をいただく場合もありま す。)
- ▶ 管理者は<u>出版後</u>48時間以内に申請の通知を受け取り、可否の検証をします。
- 管理者に承認された場合、APC全額がカバー されます。APC割引の場合は、割引後の料金 で請求書が発行されます。
- ▶ 管理者に却下された場合、正規のAPC料金での請求書を受け取ります。



# 参考情報として 責任著者への出版枠適用承認の通知

<u>管理者が申請者への通知設定を行っている場合</u>、申請が承認されると右のようなメールが 配信されますのでご確認ください。



#### **Open Access Platform**

#### Your Article Publishing Charge has been approved

#### Dear Dr S Banner-Foster,

We are pleased to inform you that Dan Hoyle of the Institute of Economics approved the funding of the Article Publishing Charge for the article listed below.

#### Article details

Article title

Test Article 12-04-22

Article reference number (PII)

TEST1649759808563

Journal title

Neurobiology of Disease Article Publishing Charge

#### Next steps

No further action is required from you. The cost of publishing your article open access will be covered in full by the institution's agreement with us. On behalf of Elsevier, we wish you continued success in your research.

Kind regards, Researcher Support



## 参考情報として 責任著者へのAPC割引適用承認の通知

<u>管理者が申請者への通知設定を行っている場合</u>、申請が承認されると右のようなメールが 配信されますのでご確認ください。



Open Access Platform



#### Your Article Publishing Charge has been approved

Dear Dr S Banner-Foster,

We are pleased to inform you that of the Dan Hoyle confirmed your affiliation.

You are therefore eligible for a discount on the Article Publishing Charge relating to the article listed below.

#### Article details

Article title

Test Article 12-04-22

Article reference number (PII)

TEST1649759808563

Journal title

Neurobiology of Disease Article Publishing Charge

#### Next steps

An invoice, at the discounted rate, will be sent to the address you specified. On behalf of Elsevier, we wish you continued success in your research.

Kind regards, Researcher Support

#### Using the Elsevier Open Access Platform - Managing pending requests

### 参考情報として 責任著者への却下の通知

<u>管理者が申請者への通知設定を行っている場合</u>、申請が却下されると右のようなメールが 配信されますのでご確認ください。



Open

Open Access Platform



### Your Article Publishing Charge has been rejected

Dear Dr S Banner-Foster,

We are sorry to inform you that Dan Hoyle of the Economics Institute has rejected the Article Publishing Charge for the article listed below.

#### **Article details**

Article title

Test Article 12-04-22

Article reference number (PII)

TEST1649759808563

Journal title

Neurobiology of Disease Article Publishing Charge

#### **Reason for rejection**

Author not / no longer affiliated

#### Next steps

Please contact the Dan Hoyle directly if you have questions regarding their decision. Elsevier will allow 7 days for you to discuss this with the institution before issuing you with an invoice to the address you provided at the time of submission\*.

Kind regards, Researcher Support

\* If the address needs to be amended, you need to advise of any VAT/Tax registration or exemption details, or if the rejection is reversed by the institution, please contact the Researcher Support Team using the Elsevier Open Access Platform Support Center.

### 参考情報として 責任著者への却下の通知後のメールについて

却下された場合、前ページのメールとは別にサポート チームから右のメール内容(例)が届きます。『出版枠 を却下されましたが、オープンアクセスとして出版され たいかどうか』の確認です。このメールに返信いただく ことでオープンアクセスもしくはサブスクリプションを 決定することが可能です。



However, as part of the validation process, your article has been rejected with the following reason "

In this regard, would you please be so kind and advise if you still wish to publish your article as Open Access? If yes, can you please provide the billing address information for the invoice?

Kindly note that if we have not heard back from you within (7) working days, we will have to send you a full price invoice.

Please let me know if you have any questions. Looking forward to your response.

※メール内容にも記載がありますが、オープンアクセスを希望する場合、オープンアクセスで出版する旨の意思をメール で返信いただき(\*英語でお願いします)、Invoiceの送り先住所情報もお送りいただけるとスムーズです。

- ※メールに返信をされない場合は、オープンアクセスで出版されます。
- ※サブスクリプションに変更を希望する場合、メールに『サブスクリプションに変更したい』と返信してください

(\*英語でお願いします)。

※ オープンアクセスで出版した後に、サブスクリプションへの変更をご希望される場合には下記URLを参考にお手続きい ただく必要がございます。

https://view.highspot.com/viewer/662b4e2aa899f5f3ab5875a3



関連情報

- 著者のお問い合わせ窓口 <u>support@elsevier.com</u> (対応言語は英語となります)
- Author journey 解説動画 -<u>https://service.elsevier.com/app/answers/detail/a\_id/29789/support</u> <u>hub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e</u> <u>~zj~PP\_X/</u>





# Thank you

